“Reprogrammed” Treatment-Resistant Lymphomas Respond to Cancer Drugs
American Association for Cancer Research (AACR)A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.